No. 6 June 2000, pp. A multicenter retrospective study was conducted to investigate the possible metabolic causes of pediatric cardiomyopathy and evaluate the outcome of patients treated with L-carnitine. There were 101males and 120females between 1day and 18years old. These metabolic disorders were thought to be the cause for the cardiomyopathy of the patients. Data were collected at intervals from baseline to study endpoint, death, transplant, or last known follow-up visit.
Results suggest that L-carnitine provides clinical benefit in treating pediatric cardiomyopathy.
There is a need for further exploration of potential explanatory factors for the higher mortality observed in the population of patients treated with ACE inhibitors.